Testing the mettle of PBT2 for Alzheimer's disease
- PMID: 18672401
- DOI: 10.1016/S1474-4422(08)70168-6
Testing the mettle of PBT2 for Alzheimer's disease
Comment on
-
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical